Select your language

Medical writing for pre-IND meeting

Medical writing for pre-IND meeting

Overview

G&L Scientific was engaged by an innovative US-based pharmaceutical company developing a novel antibacterial treatment for a rare lung disease. 

The client required strategic and tactical medical writing support for their pre-Investigational New Drug (pre-IND) Meeting and subsequent Investigational New Drug (IND) and Australia Clinical Trial Application (CTA) filings.

Challenges

The client faced several critical challenges in their regulatory submission process:
Accelerated development timeline:
The client’s lead drug candidate was being developed under accelerated programs, necessitating expert guidance to meet the compressed timeline.
Comprehensive document development:
The client needed experienced writers to develop all non-clinical and clinical content, including the pre-IND Briefing Book, IND, and CTA filings.
Coordination across global submissions:
The client required guidance on submission standards for both the U.S. Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA).

G&L’s Approach and Solution

G&L employed a focused approach to ensure the timely development of the necessary regulatory documents. Key activities included:
Regulatory document development:
G&L medical writers acted as lead authors for all non-clinical and clinical content, including IND Module 2 summaries, the Investigator’s Brochure (IB), and the pre-IND Briefing Book.
Strategic guidance for FDA and TGA filings:
G&L developed the FDA Briefing Book, including background and rationales for non-clinical safety and clinical study design, ensuring alignment with FDA standards.
Submission-ready formatting:
All content was prepared in submission-ready formats compliant with Electronic Common Technical Document (eCTD) authoring templates and FDA/TGA standards.

Impact and Outcomes

As a result of G&L’s involvement:
Successful pre-IND meeting:
A high-quality pre-IND Meeting Briefing Book was submitted, leading to a successful pre-IND Meeting with the FDA, which resulted in agreement on the clinical development approach.
Timely submission of IND and CTA:
G&L successfully authored and submitted the IND and CTA, allowing the US and Australian studies to commence as planned.
Ongoing support for NDA filing:
The client requested G&L’s ongoing support for New Drug Application (NDA) filing, including the authoring of Module 2 and Integrated Summary of Safety (ISS) and Integrated Summary of Efficacy (ISE) documentation.

Related Case Studies

Find out more about the solutions we provide to meet the biggest challenges in global healthcare.